Dislocations
Also known as: Ankle, Ankles, Talus
Methodology & AI Transparency ⓘ
Dislocations Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Dislocations are joint injuries that force the ends of your bones out of position.
- 2 Real-world patient consensus: Synonyms for Dislocations (S93.06XA): Ankle, Ankles, Talus (Arthritis & Joints).
- 3 Typical cash cost range: Workup highlights for Dislocations (S93.06XA): urate-lowering titration [Dislocations S93.06XA].
- 4 Top reported side effects / signs: Objective lab/clinical target for Dislocations: hs-CRP & Erythrocyte in Dislocations (S93.06XA: Sedimentation Rate) (hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (S93.06XA)) and Weight-Bearing Joint Radiograph [Dislocations S93.06XA].
Ask our AI Specialists anything about Dislocations
What Is Dislocations?
Dislocations are joint injuries that force the ends of your bones out of position. The cause is often a fall or a blow, sometimes from playing a contact sport . You can dislocate your ankles, knees, shoulders , hips, elbows and jaw. You can also dislocate your finger and toe joints. Dislocated joints often are swollen, very painful and visibly out of place. You may not be able to move it. A dislocated joint is an emergency. If you have one, seek medical attention. Treatment depends on which joint you dislocate and the severity of the injury. It might include manipulations to reposition your bones, medicine, a splint or sling, and rehabilitation.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in arthritis & joints, Dislocations (S93.06XA) involves low-grade synovial metalloproteinase in Dislocations (S93.06XA: release). Cross-referenced with NIH MeSH (Joint Dislocations), progression correlates with shifts in hs-CRP & Erythrocyte in Dislocations (S93.06XA: Sedimentation Rate) (hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (S93.06XA)).
Common Symptoms & Clinical Signs
- • Presentation of Dislocations (S93.06XA): activity-related deep aching in Dislocations (S93.06XA: joint pain in)
- • Secondary Dislocations clinical sign: brief morning joint in Dislocations (S93.06XA: stiffness)
- • Symptom flares in Dislocations correlating with hs-CRP & Erythrocyte in Dislocations (S93.06XA: Sedimentation Rate) deviation outside hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (S93.06XA)
- • Functional arthritis & joints impact requiring urate-lowering titration [Dislocations S93.06XA] evaluation (S93.06XA)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Dislocations Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | S93.06XA | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Dislocations (S93.06XA: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (S93.06XA) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Dislocations S93.06XA] | Preserved joint-space width (S93.06XA) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Dislocations (S93.06XA: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (S93.06XA) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Dislocations
Treatment selection for Dislocations depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Dislocations)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Trajectory of clinical responses in patients with early autoimmune joint pain: What a 451-Participant Study Found A high proportion of individual patients achieving clinical endpoints at IP week 24 with abatacept + methotrexate sustained their responses through week 52. Arthritis research & therapy • 2023-04-22 • Phase III Randomized Trial | N = 451 | 93/100 | PMID 37087459 ↗ |
| Can This Approach Help? Inside the Latest Research on Exposure-Response Analysis of Tofacitinib in Active Psoriatic Arthritis: Results The proportions of patients experiencing a decrease in Hgb of >2 g/dL were similar with tofacitinib 5 mg twice daily or placebo. Journal of clinical pharmacology • 2025-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39453735 ↗ |
| New Insights on Benefits and safety of secukinumab in patients with spondyloarthritis and: What a 204-Participant Study Found A substantial proportion of patients showed no signs of inflammation on the centrally read MRIs despite a clinical diagnosis of heel enthesitis, thus highlighting that the discrepancy between the clinical and imaging... Rheumatology (Oxford, England) • 2022-07-06 • Phase III Randomized Trial | N = 204 | 88/100 | PMID 34730795 ↗ |
| Can This Approach Help? Inside the Latest Research on Ozoralizumab shows effectiveness regardless of baseline RF and ACPA titres in OZR is an effective anti-TNF treatment for RA, regardless of RF and ACPA titres, and exhibits promise as a novel therapeutic option. Rheumatology (Oxford, England) • 2025-07-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 40139716 ↗ |
| Can This Approach Help? Inside the Latest Research on Tight Control and Radiological Progression: The Radiographic Outcomes of the These data confirm the benefit of achieving low disease activity states on subsequent radiographic outcomes but did not show a significant impact related to a TC management approach. The Journal of rheumatology • 2025-05-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39892892 ↗ |
Dislocations Patient Community & “People Like Me” Threads
Filter Dislocations community threads and patient logs by age, biological sex, dosage, and treatment duration.